223 related articles for article (PubMed ID: 38676426)
1. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
Akepati PR; Gochanour EM
Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
3. Obeticholic acid in primary biliary cholangitis: where we stand.
Manne V; Kowdley KV
Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
5. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
7. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
8. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
Silveira MG; Lindor KD
Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
[TBL] [Abstract][Full Text] [Related]
10. Obeticholic acid for the treatment of primary biliary cirrhosis.
Trivedi PJ; Hirschfield GM; Gershwin ME
Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
[TBL] [Abstract][Full Text] [Related]
11. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
12. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong LL; Hegade VS; Jones DEJ
Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
[TBL] [Abstract][Full Text] [Related]
13. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
Silveira MG; Lindor KD
Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
[TBL] [Abstract][Full Text] [Related]
16. Current and potential treatments for primary biliary cholangitis.
Shah RA; Kowdley KV
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for the treatment of primary biliary cholangitis.
Phaw NA; Dyson JK; Jones D
Expert Opin Emerg Drugs; 2020 Jun; 25(2):101-112. PubMed ID: 32253941
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
20. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
